Reducing surgery-associated hemolysis in cold agglutinin disease patients
AssigneeBioverativ USA Inc.
InventorsWilliam E. Hobbs, Michael J. Storek, Tor Henrik Anderson Tvedt, Marek Wardecki, Nancy Wong
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for reducing or preventing surgery-associated hemolysis in subjects who have cold agglutinin disease (CAD) (e.g., been diagnosed with CAD or have had at least one symptom of CAD).
Claims27
A method of reducing or preventing hemolysis in a subject in need thereof undergoing a major surgery, comprising maintaining in the subject a therapeutic serum concentration of a proximal classical complement pathway inhibitor, wherein the subject has cold agglutinin disease (CAD) and the therapeutic serum concentration is effective to reduce or prevent hemolysis.
(canceled)
A method of reducing or preventing hemolysis in a subject in need thereof undergoing a major surgery, comprising performing the major surgery on the subject when the subject has a proximal classical complement pathway inhibitor serum concentration effective to reduce or prevent hemolysis, wherein the subject has cold agglutinin disease (CAD) and has been undergoing treatment with the proximal classical complement pathway inhibitor.
A method of reducing or preventing hemolysis in a subject in need thereof undergoing a major surgery, comprising:
- assessing a serum concentration of a proximal classical complement pathway inhibitor in a subject who has cold agglutinin disease (CAD) and is undergoing treatment with a proximal classical complement pathway inhibitor;
- and
- performing the major surgery on the subject within seven days of the assessing.
(canceled)
(canceled)
(canceled)
(canceled)
25-26. (canceled)
28-29. (canceled)
Dependencies are inferred from the claim text.